247 related articles for article (PubMed ID: 15760730)
1. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone.
Teixeira M; Alonso MJ; Pinto MM; Barbosa CM
Eur J Pharm Biopharm; 2005 Apr; 59(3):491-500. PubMed ID: 15760730
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of highly-magnetic biodegradable poly(d,l-lactide-co-glycolide) nanospheres.
Liu X; Kaminski MD; Chen H; Torno M; Taylor L; Rosengart AJ
J Control Release; 2007 May; 119(1):52-8. PubMed ID: 17350131
[TBL] [Abstract][Full Text] [Related]
3. A validated HPLC method for the assay of xanthone and 3-methoxyxanthone in PLGA nanocapsules.
Teixeira M; Afonso CM; Pinto MM; Barbosa CM
J Chromatogr Sci; 2003 Aug; 41(7):371-6. PubMed ID: 12908954
[TBL] [Abstract][Full Text] [Related]
4. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.
Mukerjee A; Vishwanatha JK
Anticancer Res; 2009 Oct; 29(10):3867-75. PubMed ID: 19846921
[TBL] [Abstract][Full Text] [Related]
5. Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.
Yin J; Noda Y; Yotsuyanagi T
Int J Pharm; 2006 May; 314(1):46-55. PubMed ID: 16551494
[TBL] [Abstract][Full Text] [Related]
6. Semisolid topical formulations containing nimesulide-loaded nanocapsules, nanospheres or nanoemulsion: development and rheological characterization.
Alves PM; Pohlmann AR; Guterres SS
Pharmazie; 2005 Dec; 60(12):900-4. PubMed ID: 16398265
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies.
Mundargi RC; Srirangarajan S; Agnihotri SA; Patil SA; Ravindra S; Setty SB; Aminabhavi TM
J Control Release; 2007 May; 119(1):59-68. PubMed ID: 17331611
[TBL] [Abstract][Full Text] [Related]
9. Experimental design and multivariate analysis for optimizing poly(D,L-lactide-co-glycolide) (PLGA) nanoparticle synthesis using molecular micelles.
Ganea GM; Sabliov CM; Ishola AO; Fakayode SO; Warner IM
J Nanosci Nanotechnol; 2008 Jan; 8(1):280-92. PubMed ID: 18468072
[TBL] [Abstract][Full Text] [Related]
10. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles.
Zhao A; Rodgers VG
J Control Release; 2006 Jun; 113(1):15-22. PubMed ID: 16707186
[TBL] [Abstract][Full Text] [Related]
11. Effect of lactide/glycolide ratio on the in vitro release of ganciclovir and its lipophilic prodrug (GCV-monobutyrate) from PLGA microspheres.
Janoria KG; Mitra AK
Int J Pharm; 2007 Jun; 338(1-2):133-41. PubMed ID: 17363204
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir.
Duvvuri S; Janoria KG; Mitra AK
J Control Release; 2005 Nov; 108(2-3):282-93. PubMed ID: 16229919
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification.
Gasparini G; Kosvintsev SR; Stillwell MT; Holdich RG
Colloids Surf B Biointerfaces; 2008 Feb; 61(2):199-207. PubMed ID: 17919891
[TBL] [Abstract][Full Text] [Related]
14. Particle size control of poly(dl-lactide-co-glycolide) nanospheres for sterile applications.
Tsukada Y; Hara K; Bando Y; Huang CC; Kousaka Y; Kawashima Y; Morishita R; Tsujimoto H
Int J Pharm; 2009 Mar; 370(1-2):196-201. PubMed ID: 19100320
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles.
Gómez-Gaete C; Tsapis N; Besnard M; Bochot A; Fattal E
Int J Pharm; 2007 Mar; 331(2):153-9. PubMed ID: 17157461
[TBL] [Abstract][Full Text] [Related]
16. An innovative, quick and convenient labeling method for the investigation of pharmacological behavior and the metabolism of poly(DL-lactide-co-glycolide) nanospheres.
Stevanović M; Maksin T; Petković J; Filipic M; Uskoković D
Nanotechnology; 2009 Aug; 20(33):335102. PubMed ID: 19636100
[TBL] [Abstract][Full Text] [Related]
17. The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanoparticles.
Dillen K; Weyenberg W; Vandervoort J; Ludwig A
Eur J Pharm Biopharm; 2004 Nov; 58(3):539-49. PubMed ID: 15451528
[TBL] [Abstract][Full Text] [Related]
18. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
Dong WY; Körber M; López Esguerra V; Bodmeier R
J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
[TBL] [Abstract][Full Text] [Related]
19. Diffusion and mathematical modeling of release profiles from nanocarriers.
Cruz L; Soares LU; Costa TD; Mezzalira G; da Silveira NP; Guterres SS; Pohlmann AR
Int J Pharm; 2006 Apr; 313(1-2):198-205. PubMed ID: 16503103
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.
Costantino L; Gandolfi F; Bossy-Nobs L; Tosi G; Gurny R; Rivasi F; Vandelli MA; Forni F
Biomaterials; 2006 Sep; 27(26):4635-45. PubMed ID: 16716395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
